Mereo Biopharma Group Plc MREO 深 沪
已收盘 09-18 16:00:00 美东时间
4.22
+0.270
+6.84%
华盛通- 最 高4.305
- 今 开4.12
- 成交量 156.60万股
- 最 低 4.02
- 昨 收 3.95
- 总市值 5.91亿
- 52周最高 5.02
- 市盈率 静 --
- 换手率 1.12%
- 52周最低 1.07
- 委 比 79.88%
- 总股本 1.40亿
- 历史最高 17.62
- 量 比 1.28
- 振 幅 7.22%
- 历史最低 0.301
- 每 手 1
- 风险率 0.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
iTeos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy dosta...
09-14 19:16
New additions to Roth MKM’s ADR portfolio for September
Roth MKM analysts updated their top ideas within their ADR universe. ADRs are U.S. dollar certificates that trade on American stock exchanges tracking the price of a foreign company’s domestic shares....
09-12 22:41
快讯 | mereo biopharma集团PLC：Leerink Partners将目标价从6美元提高至8美元。
Mereo Biopharma Group PLC : Leerink Partners Raises Target Price to $8 From $6
06-20 11:27
Mereo BioPharma’s Public Offering and Strategic Underwriter Partnership
Mereo Biopharma Group Plc (MREO) has shared an announcement. Mereo BioPharma Gr...
06-15 05:18
Ultragenyx Pharmaceutical prices $350 million securities offering
Ultragenyx Pharmaceutical (NASDAQ:RARE) announces the pricing of its underwritten public offering of 7,435,898 shares of its common stock at $39.00 per share, and pre-funded warrants offering to purch...
06-14 16:45
Baird starts Mereo at outperform, sees alvelestat as underappreciated
Baird initiated coverage of Mereo Biopharma (NASDAQ:MREO) with an outperform rating, citing its rare disease drugs setrusumab and alvelestat. Baird said it believes setrusumab represents a $750M+ reve...
06-14 04:48
Ultragenyx to file for accelerated approval of rare metabolic disease candidate
Ultragenyx (NASDAQ:RARE) said it would submit a Biologics License Application to the U.S. FDA seeking accelerated approval of UX111, a gene therapy for Sanfilippo syndrome, a rare metabolic disease. T...
06-13 04:40
Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASD...
06-13 00:17
Mereo BioPharma Reports Breakthrough in OI Fracture Study
Mereo Biopharma Group Plc (MREO) has provided an announcement. Ultragenyx Pharm...
06-12 19:53
Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
Mereo BioPharma (NASDAQ:MREO) traded higher premarket Wednesday after the company and its partner Ultragenyx Pharmaceutical (NASDAQ:RARE) announced 14-month data from a Phase 2 portion of an ongoing P...
06-12 19:00
